The Coronavirus disease 2019 (COVID-19) pandemic has represented an unprecedented challenge for humankind from health, economic, and social viewpoints. In February 2020, Italy was the first western country to be deeply hit by the pandemic and suffered the highest case/fatality rate among western countries. Brand new anti-COVID-19 vaccines have been developed and made available in <1-year from the viral sequence publication. Patients with compromised immune systems, such as autoimmune-autoinflammatory disorders (AIAIDs), primary (PIDs) and secondary (SIDs) immunodeficiencies, have received careful attention for a long time regarding their capacity to safely respond to traditional vaccines. The Italian Immunological Societies, therefore, have promptly faced the issues of safety, immunogenicity, and efficacy/effectiveness of the innovative COVID-19 vaccines, as well as priority to vaccine access, in patients with AIADs, PIDs, and SIDs, by organizing an ad-hoc Task Force.

Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies / D'Amelio, Raffaele; Asero, Riccardo; Cassatella, Marco Antonio; Laganà, Bruno; Lunardi, Claudio; Migliorini, Paola; Nisini, Roberto; Parronchi, Paola; Quinti, Isabella; Racanelli, Vito; Senna, Gianenrico; Vacca, Angelo; Maggi, Enrico. - In: BIOMEDICINES. - ISSN 2227-9059. - 9:9(2021), pp. 116301-116324. [10.3390/biomedicines9091163]

Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies

Racanelli, Vito;
2021-01-01

Abstract

The Coronavirus disease 2019 (COVID-19) pandemic has represented an unprecedented challenge for humankind from health, economic, and social viewpoints. In February 2020, Italy was the first western country to be deeply hit by the pandemic and suffered the highest case/fatality rate among western countries. Brand new anti-COVID-19 vaccines have been developed and made available in <1-year from the viral sequence publication. Patients with compromised immune systems, such as autoimmune-autoinflammatory disorders (AIAIDs), primary (PIDs) and secondary (SIDs) immunodeficiencies, have received careful attention for a long time regarding their capacity to safely respond to traditional vaccines. The Italian Immunological Societies, therefore, have promptly faced the issues of safety, immunogenicity, and efficacy/effectiveness of the innovative COVID-19 vaccines, as well as priority to vaccine access, in patients with AIADs, PIDs, and SIDs, by organizing an ad-hoc Task Force.
2021
9
D'Amelio, Raffaele; Asero, Riccardo; Cassatella, Marco Antonio; Laganà, Bruno; Lunardi, Claudio; Migliorini, Paola; Nisini, Roberto; Parronchi, Paola;...espandi
Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies / D'Amelio, Raffaele; Asero, Riccardo; Cassatella, Marco Antonio; Laganà, Bruno; Lunardi, Claudio; Migliorini, Paola; Nisini, Roberto; Parronchi, Paola; Quinti, Isabella; Racanelli, Vito; Senna, Gianenrico; Vacca, Angelo; Maggi, Enrico. - In: BIOMEDICINES. - ISSN 2227-9059. - 9:9(2021), pp. 116301-116324. [10.3390/biomedicines9091163]
File in questo prodotto:
File Dimensione Formato  
2021 Anti COVID Vaccination_biomedicines_compressed.pdf

accesso aperto

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 286.61 kB
Formato Adobe PDF
286.61 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/387049
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 18
social impact